Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

NCT05342389 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Gastric Adenocarcinoma
Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Camrelizumab
DRUG: Apatinib Mesylate

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University